Puretech Health Plc Stock Performance
| PTCHF Stock | USD 1.71 0.01 0.59% |
The company holds a Beta of -0.13, which implies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning PureTech Health are expected to decrease at a much lower rate. During the bear market, PureTech Health is likely to outperform the market. At this point, PureTech Health plc has a negative expected return of -0.15%. Please make sure to check PureTech Health's kurtosis, as well as the relationship between the day median price and period momentum indicator , to decide if PureTech Health plc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days PureTech Health plc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's technical indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders. ...more
| Begin Period Cash Flow | 403.9 M | |
| Total Cashflows From Investing Activities | 197.4 M |
PureTech |
PureTech Health Relative Risk vs. Return Landscape
If you would invest 190.00 in PureTech Health plc on October 6, 2025 and sell it today you would lose (19.00) from holding PureTech Health plc or give up 10.0% of portfolio value over 90 days. PureTech Health plc is currently producing negative expected returns and takes up 1.8669% volatility of returns over 90 trading days. Put another way, 16% of traded pink sheets are less volatile than PureTech, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
PureTech Health Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for PureTech Health's investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as PureTech Health plc, and traders can use it to determine the average amount a PureTech Health's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0799
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PTCHF |
Based on monthly moving average PureTech Health is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PureTech Health by adding PureTech Health to a well-diversified portfolio.
PureTech Health Fundamentals Growth
PureTech Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of PureTech Health, and PureTech Health fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on PureTech Pink Sheet performance.
| Return On Equity | -0.0152 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.73) % | |||
| Operating Margin | (9.87) % | |||
| Current Valuation | 654.5 M | |||
| Shares Outstanding | 278.81 M | |||
| Price To Earning | 158.00 X | |||
| Price To Book | 1.61 X | |||
| Price To Sales | 51.23 X | |||
| Revenue | 9.98 M | |||
| EBITDA | (46.95 M) | |||
| Cash And Equivalents | 368.03 M | |||
| Cash Per Share | 1.28 X | |||
| Total Debt | 14.26 M | |||
| Debt To Equity | 0.08 % | |||
| Book Value Per Share | 2.03 X | |||
| Cash Flow From Operations | (158.27 M) | |||
| Earnings Per Share | (0.21) X | |||
| Total Asset | 946.01 M | |||
About PureTech Health Performance
By analyzing PureTech Health's fundamental ratios, stakeholders can gain valuable insights into PureTech Health's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if PureTech Health has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if PureTech Health has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts. PURETECH HEALTH operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 95 people.Things to note about PureTech Health plc performance evaluation
Checking the ongoing alerts about PureTech Health for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for PureTech Health plc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| PureTech Health plc generated a negative expected return over the last 90 days | |
| PureTech Health plc may become a speculative penny stock | |
| The company reported the revenue of 9.98 M. Net Loss for the year was (60.56 M) with profit before overhead, payroll, taxes, and interest of 17.39 M. | |
| PureTech Health plc has accumulated about 368.03 M in cash with (158.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.28. | |
| Roughly 72.0% of the company shares are owned by institutional investors |
- Analyzing PureTech Health's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether PureTech Health's stock is overvalued or undervalued compared to its peers.
- Examining PureTech Health's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating PureTech Health's management team can have a significant impact on its success or failure. Reviewing the track record and experience of PureTech Health's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of PureTech Health's pink sheet. These opinions can provide insight into PureTech Health's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for PureTech Pink Sheet analysis
When running PureTech Health's price analysis, check to measure PureTech Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PureTech Health is operating at the current time. Most of PureTech Health's value examination focuses on studying past and present price action to predict the probability of PureTech Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PureTech Health's price. Additionally, you may evaluate how the addition of PureTech Health to your portfolios can decrease your overall portfolio volatility.
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |